mitoxantrone has been researched along with Colonic Neoplasms in 47 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Colonic Neoplasms: Tumors or cancer of the COLON.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A variety of drug-resistant human cancer cell lines derived by selection with mitoxantrone markedly overexpressed BCRP mRNA; these cell lines included sublines of human breast carcinoma (MCF-7), colon carcinoma (S1 and HT29), gastric carcinoma (EPG85-257), fibrosarcoma (EPF86-079), and myeloma (8226) origins." | 7.70 | Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. ( Abruzzo, LV; Cole, SP; Dalton, WS; Dietel, M; Doyle, LA; Greenberger, L; Lage, H; Ross, DD; Schneider, E; Yang, W, 1999) |
| "A human colon carcinoma cell line selected for a 21-fold resistance to mitoxantrone was cross-resistant to the anthracycline, doxorubicin, but not to the anthracene, bisantrene." | 7.67 | Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone. ( Alberts, DS; Cress, AE; Dalton, WS; Trent, JM, 1988) |
| "A subline of human colon carcinoma cells (WiDr/R) resistant to the cytotoxic effects of mitoxantrone in vitro, was developed by continuous exposure to increasing concentrations of drug." | 7.67 | Development of resistance and characteristics of a human colon carcinoma subline resistant to mitoxantrone in vitro. ( Durr, FE; Lindh, D; Wallace, RE, 1987) |
| "The effect of temperature on the cytotoxicity of mitoxantrone (MX) was investigated by exposing human WIDR colon carcinoma cells to elevated temperatures in the presence of drug." | 7.67 | Effect of hyperthermia on the sensitivity of human colon carcinoma cells to mitoxantrone. ( Durr, FE; Lumanglas, AL; Ruszala-Mallon, VM; Silva, J; Wang, BS, 1987) |
| "Three mouse cancer cell lines [CT26 mouse colon cancer cells, B16 melanoma cells and Lewis lung carcinoma (LLC)], 5 human carcinoma cell lines (human esophageal squamous cell carcinoma cell lines TE8 and HEC46 and the human pancreatic carcinoma cell lines PK-9, AsPC-1 and SUIT-2) and 5 chemotherapeutic agents [mitoxantrone (MIT), mitomycin C(MMC), 5-fluorouracil (5FU), camptothecin (CPT-11) and cisplatin (CDDP)] that are frequently used in a clinical setting for cancer treatment were utilized to investigate the surface expression level of calreticulin and HLA class I after exposure to chemotherapeutic agents." | 3.81 | The key role of calreticulin in immunomodulation induced by chemotherapeutic agents. ( Hirano, S; Kuroda, A; Kuwatani, T; Kyogoku, N; Maki, T; Miyauchi, K; Shichinohe, T; Takeuchi, S; Tsuchikawa, T; Wada, M; Yamamura, Y, 2015) |
| "We selected a human colon carcinoma cell line in increasing concentrations of mitoxantrone to obtain a resistant subline, S1-M1-3." | 3.70 | Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. ( Annable, T; Brown, E; Collins, KI; Greenberger, LM; He, H; Rabindran, SK; Singh, M, 1998) |
| "A variety of drug-resistant human cancer cell lines derived by selection with mitoxantrone markedly overexpressed BCRP mRNA; these cell lines included sublines of human breast carcinoma (MCF-7), colon carcinoma (S1 and HT29), gastric carcinoma (EPG85-257), fibrosarcoma (EPF86-079), and myeloma (8226) origins." | 3.70 | Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. ( Abruzzo, LV; Cole, SP; Dalton, WS; Dietel, M; Doyle, LA; Greenberger, L; Lage, H; Ross, DD; Schneider, E; Yang, W, 1999) |
| "28 patients (26 with breast cancer and 2 with colon cancer) received mitomycin, mitoxantrone and methotrexate (MMM)." | 3.68 | Unexpected prolonged myelosuppression after mitomycin, mitoxantrone and methotrexate. ( Blomqvist, CP; Muhonen, TT; Pyrhönen, SO; Wiklund, TA, 1992) |
| "A human colon carcinoma cell line selected for a 21-fold resistance to mitoxantrone was cross-resistant to the anthracycline, doxorubicin, but not to the anthracene, bisantrene." | 3.67 | Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone. ( Alberts, DS; Cress, AE; Dalton, WS; Trent, JM, 1988) |
| "A subline of human colon carcinoma cells (WiDr/R) resistant to the cytotoxic effects of mitoxantrone in vitro, was developed by continuous exposure to increasing concentrations of drug." | 3.67 | Development of resistance and characteristics of a human colon carcinoma subline resistant to mitoxantrone in vitro. ( Durr, FE; Lindh, D; Wallace, RE, 1987) |
| "The effect of temperature on the cytotoxicity of mitoxantrone (MX) was investigated by exposing human WIDR colon carcinoma cells to elevated temperatures in the presence of drug." | 3.67 | Effect of hyperthermia on the sensitivity of human colon carcinoma cells to mitoxantrone. ( Durr, FE; Lumanglas, AL; Ruszala-Mallon, VM; Silva, J; Wang, BS, 1987) |
| "We aimed to evaluate in colon cancer cells a combination of six agents directed to block the tumor anabolism (orlistat + lonidamine + DON) and the host catabolism (growth hormone + insulin + indomethacin)." | 1.62 | Pharmacological inhibition of tumor anabolism and host catabolism as a cancer therapy. ( Chavez-Blanco, A; Diaz-Chavez, J; Dominguez-Gomez, G; Duenas-Gonzalez, A; Hua, S; Juarez, M; Lai, D; Perez-Montiel, D; Ponce-Toledo, RI; Schcolnik-Cabrera, A; Torres, N; Tovar, AR; Vargas-Castillo, A, 2021) |
| "We selected breast, ovarian and colon cancer cells (MCF-7, IGROV-1 and S-1) after exposure to 14 or 21 nM doxorubicin for only 10 days." | 1.35 | Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. ( Ambudkar, SV; Bates, SE; Calcagno, AM; Caplen, NJ; Chewning, KJ; Fostel, JM; Martin, SE; Salcido, CD; To, KK; Varticovski, L; Wu, CP, 2008) |
| "Efflux transporters, p-glycoprotein and breast cancer resistance protein (BCRP), located at barrier sites such as the blood-brain barrier may affect distribution of steroids used for treating chronic inflammatory conditions and thus the extent to which they may perturb the hypothalamic-pituitary-adrenal axis." | 1.33 | Modulation of p-glycoprotein and breast cancer resistance protein by some prescribed corticosteroids. ( Barrand, MA; Cahn, AP; Cooray, HC; Hladky, SB; Shahi, S; van Veen, HW, 2006) |
| "Mitoxantrone was effective in preventing lung metastases even at doses that did not exhibit an antitumor effect on the primary tumor." | 1.29 | Characteristics of the inhibitory effect of mitoxantrone and pirarubicin on lung metastases of colon carcinoma 26. ( Iigo, M; Sagawa, K; Shimamura, M; Tsuda, H, 1995) |
| "Mitoxantrone has markedly less cardiotoxicity than doxorubicin, and this may be linked to the fact that the drug does not induce free radical formation but inhibits lipid peroxidation." | 1.27 | Biologic and biochemical effects of mitoxantrone. ( Durr, FE, 1984) |
| "Mitoxantrone was 10-fold more active on cells in G2 phase than on those in mid- to late-S phase." | 1.27 | Comparative cytotoxicity of bisantrene, mitoxantrone, ametantrone, dihydroxyanthracenedione, dihydroxyanthracenedione diacetate, and doxorubicin on human cells in vitro. ( Barlogie, B; Drewinko, B; Trujillo, JM; Yang, LY, 1983) |
| " Distribution and half-life data provide a pharmacological rationale for the use of mitoxantrone on an intermittent dosing schedule." | 1.27 | Pharmacology of mitoxantrone: mode of action and pharmacokinetics. ( Alberts, DS; Bowden, GT; Dalton, WS; Mackel, C; Peng, YM, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (34.04) | 18.7374 |
| 1990's | 15 (31.91) | 18.2507 |
| 2000's | 8 (17.02) | 29.6817 |
| 2010's | 7 (14.89) | 24.3611 |
| 2020's | 1 (2.13) | 2.80 |
| Authors | Studies |
|---|---|
| Zee-Cheng, RK | 1 |
| Podrebarac, EG | 1 |
| Menon, CS | 1 |
| Cheng, CC | 1 |
| Krapcho, AP | 3 |
| Getahun, Z | 2 |
| Avery, KL | 1 |
| Vargas, KJ | 1 |
| Hacker, MP | 3 |
| Spinelli, S | 2 |
| Pezzoni, G | 2 |
| Manzotti, C | 1 |
| Sami, SM | 1 |
| Dorr, RT | 1 |
| Sólyom, AM | 1 |
| Alberts, DS | 3 |
| Remers, WA | 1 |
| Petry, ME | 1 |
| Landi, JJ | 1 |
| Stallman, J | 1 |
| Polsenberg, JF | 1 |
| Gallagher, CE | 2 |
| Maresch, MJ | 1 |
| Giuliani, FC | 2 |
| Menta, E | 1 |
| Oliva, A | 1 |
| Di Domenico, R | 1 |
| Fiocchi, L | 1 |
| Maresch, ME | 1 |
| Beggiolin, G | 1 |
| Litman, T | 2 |
| Brangi, M | 1 |
| Hudson, E | 1 |
| Fetsch, P | 1 |
| Abati, A | 1 |
| Ross, DD | 2 |
| Miyake, K | 3 |
| Resau, JH | 1 |
| Bates, SE | 3 |
| Lavaggi, ML | 1 |
| Cabrera, M | 1 |
| Aravena, Mde L | 1 |
| Olea-Azar, C | 1 |
| López de Ceráin, A | 1 |
| Monge, A | 1 |
| Pachón, G | 1 |
| Cascante, M | 1 |
| Bruno, AM | 1 |
| Pietrasanta, LI | 1 |
| González, M | 1 |
| Cerecetto, H | 1 |
| Schcolnik-Cabrera, A | 1 |
| Chavez-Blanco, A | 1 |
| Dominguez-Gomez, G | 1 |
| Juarez, M | 1 |
| Vargas-Castillo, A | 1 |
| Ponce-Toledo, RI | 1 |
| Lai, D | 1 |
| Hua, S | 1 |
| Tovar, AR | 1 |
| Torres, N | 1 |
| Perez-Montiel, D | 1 |
| Diaz-Chavez, J | 1 |
| Duenas-Gonzalez, A | 1 |
| Hussein, N | 1 |
| Amawi, H | 1 |
| Karthikeyan, C | 1 |
| Hall, FS | 1 |
| Mittal, R | 1 |
| Trivedi, P | 1 |
| Ashby, CR | 1 |
| Tiwari, AK | 1 |
| Ji, N | 1 |
| Yang, Y | 1 |
| Cai, CY | 1 |
| Lei, ZN | 2 |
| Wang, JQ | 1 |
| Gupta, P | 1 |
| Shukla, S | 2 |
| Ambudkar, SV | 3 |
| Kong, D | 1 |
| Chen, ZS | 2 |
| Zhang, YK | 1 |
| Wang, YJ | 1 |
| Zhang, GN | 1 |
| Zhang, XY | 1 |
| Wang, DS | 1 |
| Al-Rihani, SB | 1 |
| Kaddoumi, A | 1 |
| Shi, Z | 1 |
| Washio, I | 1 |
| Nakanishi, T | 1 |
| Ishiguro, N | 1 |
| Bister, B | 1 |
| Tamai, I | 1 |
| Yamamura, Y | 1 |
| Tsuchikawa, T | 1 |
| Miyauchi, K | 1 |
| Takeuchi, S | 1 |
| Wada, M | 1 |
| Kuwatani, T | 1 |
| Kyogoku, N | 1 |
| Kuroda, A | 1 |
| Maki, T | 1 |
| Shichinohe, T | 1 |
| Hirano, S | 1 |
| Wang, F | 1 |
| Liang, YJ | 1 |
| Wu, XP | 1 |
| Su, XD | 1 |
| Fu, LW | 1 |
| Jaster, JH | 1 |
| Niell, HB | 1 |
| Dohan, FC | 1 |
| Smith, TW | 1 |
| Györffy, B | 1 |
| Serra, V | 1 |
| Jürchott, K | 1 |
| Abdul-Ghani, R | 1 |
| Garber, M | 1 |
| Stein, U | 1 |
| Petersen, I | 1 |
| Lage, H | 2 |
| Dietel, M | 2 |
| Schäfer, R | 1 |
| Cooray, HC | 1 |
| Shahi, S | 1 |
| Cahn, AP | 1 |
| van Veen, HW | 1 |
| Hladky, SB | 1 |
| Barrand, MA | 1 |
| Calcagno, AM | 1 |
| Fostel, JM | 1 |
| To, KK | 1 |
| Salcido, CD | 1 |
| Martin, SE | 1 |
| Chewning, KJ | 1 |
| Wu, CP | 1 |
| Varticovski, L | 1 |
| Caplen, NJ | 1 |
| Durr, FE | 5 |
| Wallace, RE | 2 |
| Citarella, RV | 1 |
| DeSimone, PA | 1 |
| Gams, R | 1 |
| Bartolucci, A | 1 |
| Bedikian, AY | 1 |
| Stroehlein, J | 1 |
| Korinek, J | 1 |
| Karlin, D | 1 |
| Valdivieso, M | 1 |
| Bodey, GP | 1 |
| Drewinko, B | 1 |
| Yang, LY | 1 |
| Barlogie, B | 1 |
| Trujillo, JM | 1 |
| Cowan, JD | 1 |
| Von Hoff, DD | 1 |
| McDonald, B | 1 |
| Talley, RW | 1 |
| McCracken, JD | 1 |
| Chen, T | 1 |
| Bonnem, EM | 1 |
| Mitchell, EP | 1 |
| Woolley, PV | 1 |
| Smith, FP | 1 |
| Neefe, J | 1 |
| Smith, L | 1 |
| Schein, PS | 1 |
| Schabel, FM | 1 |
| Skipper, HE | 1 |
| Trader, MW | 1 |
| Brockman, RW | 1 |
| Laster, WR | 1 |
| Corbett, TH | 1 |
| Griswold, DP | 1 |
| Iigo, M | 1 |
| Shimamura, M | 1 |
| Sagawa, K | 1 |
| Tsuda, H | 1 |
| Fox, ME | 1 |
| Smith, PJ | 1 |
| Genne, P | 1 |
| Olsson, NO | 1 |
| Gutierrez, G | 1 |
| Duchamp, O | 1 |
| Chauffert, B | 1 |
| Kirshenbaum, MR | 1 |
| Chen, SF | 1 |
| Behrens, CH | 1 |
| Papp, LM | 1 |
| Stafford, MM | 1 |
| Sun, JH | 1 |
| Behrens, DL | 1 |
| Fredericks, JR | 1 |
| Polkus, ST | 1 |
| Sipple, P | 1 |
| Rabindran, SK | 1 |
| He, H | 1 |
| Singh, M | 1 |
| Brown, E | 1 |
| Collins, KI | 1 |
| Annable, T | 1 |
| Greenberger, LM | 1 |
| Yang, W | 1 |
| Abruzzo, LV | 1 |
| Dalton, WS | 4 |
| Schneider, E | 2 |
| Greenberger, L | 2 |
| Cole, SP | 1 |
| Doyle, LA | 1 |
| Berti, E | 1 |
| Carrara, M | 1 |
| Ragazzi, E | 1 |
| D'Ancona, S | 1 |
| Berti, T | 1 |
| Knutsen, T | 1 |
| Rao, VK | 1 |
| Ried, T | 1 |
| Mickley, L | 1 |
| Ghadimi, BM | 1 |
| Padilla-Nash, H | 1 |
| Pack, S | 1 |
| Cowan, K | 1 |
| Dean, M | 1 |
| Fojo, T | 1 |
| Bates, S | 1 |
| Lim, HJ | 1 |
| Masin, D | 1 |
| McIntosh, NL | 1 |
| Madden, TD | 1 |
| Bally, MB | 1 |
| Hausner, P | 1 |
| Venzon, DJ | 1 |
| Grogan, L | 1 |
| Kirsch, IR | 1 |
| Robey, RW | 1 |
| Honjo, Y | 1 |
| van de Laar, A | 1 |
| Regis, JT | 1 |
| Peters, WH | 1 |
| Roelofs, HM | 1 |
| Muhonen, TT | 1 |
| Wiklund, TA | 1 |
| Blomqvist, CP | 1 |
| Pyrhönen, SO | 1 |
| Capolongo, L | 1 |
| Belvedere, G | 1 |
| D'Incalci, M | 1 |
| White, RJ | 1 |
| Roberts, RA | 1 |
| Cress, AE | 2 |
| Trent, JM | 1 |
| Lindh, D | 1 |
| Wang, BS | 1 |
| Lumanglas, AL | 1 |
| Silva, J | 1 |
| Ruszala-Mallon, VM | 1 |
| Fujita, J | 1 |
| Saijo, N | 1 |
| Peng, YM | 1 |
| Bowden, GT | 1 |
| Mackel, C | 1 |
2 reviews available for mitoxantrone and Colonic Neoplasms
| Article | Year |
|---|---|
Molecular and biochemical pharmacology of mitoxantrone.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Cell Division; Colonic Neoplasms; DNA, Neoplasm; Dru | 1983 |
[The role of chemotherapy in metastatic pulmonary tumors in a disease-oriented phase II study of anticancer agent].
Topics: Anthraquinones; Antineoplastic Agents; Cisplatin; Colonic Neoplasms; Drug Evaluation; Head and Neck | 1985 |
45 other studies available for mitoxantrone and Colonic Neoplasms
| Article | Year |
|---|---|
Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Colonic Neoplasms; Leukemia L1210; Leukemia, Experim | 1979 |
Synthesis and antitumor evaluations of symmetrically and unsymmetrically substituted 1,4-bis[(aminoalkyl)amino]anthracene-9,10-diones and 1,4-bis[(aminoalkyl)amino]-5,8-dihydroxyanthracene-9,10-diones.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Chemical Phenomena; Chemistry; Colonic Neoplasms; Hu | 1991 |
Amino-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H- dibenz[de,h]isoquinoline-1,3-diones. Synthesis, antitumor activity, and quantitative structure--activity relationship.
Topics: Adenine; Animals; Antineoplastic Agents; Cattle; Colonic Neoplasms; DNA; Doxorubicin; Heart Diseases | 1995 |
6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations.
Topics: Adenocarcinoma; Animals; Anthraquinones; Antineoplastic Agents; Colonic Neoplasms; Humans; Isoquinol | 1994 |
Synthesis and antitumor evaluation of 2,5-disubstituted-indazolo[4, 3-gh]isoquinolin-6(2H)-ones (9-aza-anthrapyrazoles).
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colonic Neoplasms; Drug Resistance, Multiple; Drug R | 1998 |
The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2).
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette | 2000 |
Study of benzo[a]phenazine 7,12-dioxide as selective hypoxic cytotoxin-scaffold. Identification of aerobic-antitumoral activity through DNA fragmentation.
Topics: Animals; Antineoplastic Agents; Caco-2 Cells; Cell Hypoxia; Cell Line; Colonic Neoplasms; Cricetinae | 2010 |
Pharmacological inhibition of tumor anabolism and host catabolism as a cancer therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Colonic Ne | 2021 |
The dopamine D
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzamides; Carcinoma, Non-Small-Cell Lung; | 2017 |
Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.
Topics: Adenosine Triphosphatases; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic | 2019 |
Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette | 2019 |
Effect of endogenous multidrug resistance 1 and P-glycoprotein expression on anticancer drug resistance in colon cancer cell lines.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transport | 2019 |
The key role of calreticulin in immunomodulation induced by chemotherapeutic agents.
Topics: Animals; Antigens, Surface; Antineoplastic Agents; Apoptosis; Calreticulin; Camptothecin; Carcinoma, | 2015 |
ABCG2-overexpressing S1-M1-80 cell xenografts in nude mice keep original biochemistry and cell biological properties.
Topics: Adenosine; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; | 2012 |
Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS.
Topics: Adult; Antineoplastic Agents; Carcinoma; Cohort Studies; Colonic Neoplasms; Demyelinating Diseases; | 2003 |
Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.
Topics: Algorithms; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; | 2005 |
Modulation of p-glycoprotein and breast cancer resistance protein by some prescribed corticosteroids.
Topics: Adenosine Triphosphatases; Adrenal Cortex Hormones; Antibiotics, Antineoplastic; ATP Binding Cassett | 2006 |
Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.
Topics: Acetylation; Antibiotics, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, S | 2008 |
Biologic and biochemical effects of mitoxantrone.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell | 1984 |
Phase II studies of mitoxantrone (dihydroxyanthracenedione) in the treatment of advanced colorectal carcinoma.
Topics: Anthraquinones; Antineoplastic Agents; Colonic Neoplasms; Drug Evaluation; Humans; Mitoxantrone; Neo | 1984 |
Phase II evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Bone Marrow; Colonic Neoplasms; Drug Evaluation; | 1983 |
Comparative cytotoxicity of bisantrene, mitoxantrone, ametantrone, dihydroxyanthracenedione, dihydroxyanthracenedione diacetate, and doxorubicin on human cells in vitro.
Topics: Anthracenes; Anthraquinones; Cell Line; Cell Survival; Colonic Neoplasms; Dose-Response Relationship | 1983 |
Phase II trial of mitoxantrone in previously untreated patients with colorectal adenocarcinoma: A Southwest Oncology Group Study.
Topics: Adenocarcinoma; Adult; Aged; Anthraquinones; Antineoplastic Agents; Colonic Neoplasms; Drug Evaluati | 1982 |
Phase II trial of mitoxantrone in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Anthraquinones; Antineoplastic Agents; Colonic Neoplasms; Drug Evaluati | 1982 |
Drug control of Ara-C-resistant tumor cells.
Topics: 3-Deazauridine; Adenocarcinoma; Animals; Anthraquinones; Antimetabolites, Antineoplastic; Colonic Ne | 1982 |
Characteristics of the inhibitory effect of mitoxantrone and pirarubicin on lung metastases of colon carcinoma 26.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cell | 1995 |
Subcellular localisation of the antitumour drug mitoxantrone and the induction of DNA damage in resistant and sensitive human colon carcinoma cells.
Topics: Adenocarcinoma; Animals; Cell Nucleus; Colonic Neoplasms; Cross-Linking Reagents; Cytoplasm; DNA Dam | 1995 |
Liposomal mitoxantrone for the local treatment of peritoneal carcinomatosis induced by colon cancer cells in mice.
Topics: Animals; Carcinoma; Colonic Neoplasms; Drug Carriers; Electrochemistry; Female; Liposomes; Male; Mic | 1994 |
(R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro.
Topics: Amsacrine; Animals; Antineoplastic Agents; Cell Division; Clinical Trials, Phase I as Topic; Colonic | 1994 |
Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Transport | 1998 |
Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines.
Topics: Antineoplastic Agents; Blotting, Northern; Blotting, Southern; Breast Neoplasms; Colonic Neoplasms; | 1999 |
A comparison of the modulation of antiblastics cytotoxicity by verapamil and dipyridamole in a human colon carcinoma cell line.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter | 1999 |
Amplification of 4q21-q22 and the MXR gene in independently derived mitoxantrone-resistant cell lines.
Topics: Antineoplastic Agents; Breast Neoplasms; Carrier Proteins; Chromosome Mapping; Chromosome Painting; | 2000 |
Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors.
Topics: Animals; Carcinoma, Squamous Cell; Cell Division; Colonic Neoplasms; Dose-Response Relationship, Dru | 2000 |
The "comparative growth assay": examining the interplay of anti-cancer agents with cells carrying single gene alterations.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member | 1999 |
A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2).
Topics: Adenosine Triphosphatases; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cass | 2001 |
Biochemical characterization of resistance to mitoxantrone and adriamycin in Caco-2 human colon adenocarcinoma cells: a possible role for glutathione S-transferases.
Topics: Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Cell Survival; C | 1992 |
Unexpected prolonged myelosuppression after mitomycin, mitoxantrone and methotrexate.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Fe | 1992 |
DNA damage and cytotoxicity of mitoxantrone and doxorubicin in doxorubicin-sensitive and -resistant human colon carcinoma cells.
Topics: Colonic Neoplasms; DNA Damage; DNA, Neoplasm; DNA, Single-Stranded; Doxorubicin; Drug Resistance; Hu | 1990 |
Development of mitoxantrone.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Cell Line; Chemistry, Pharmaceutical; Colonic Neopla | 1985 |
Persistent intracellular binding of mitoxantrone in a human colon carcinoma cell line.
Topics: Cell Cycle; Cell Division; Cell Fractionation; Cell Line; Colonic Neoplasms; Cytoplasm; DNA; Flow Cy | 1989 |
Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Carcinoma; Chromosome | 1988 |
Development of resistance and characteristics of a human colon carcinoma subline resistant to mitoxantrone in vitro.
Topics: 2,4-Dinitrophenol; Carcinoma; Cell Nucleus; Colonic Neoplasms; Dinitrophenols; DNA, Neoplasm; Drug R | 1987 |
Effect of hyperthermia on the sensitivity of human colon carcinoma cells to mitoxantrone.
Topics: Carcinoma; Colonic Neoplasms; Humans; Hyperthermia, Induced; In Vitro Techniques; Mitoxantrone | 1987 |
Pharmacology of mitoxantrone: mode of action and pharmacokinetics.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Bone Marrow; Bone Neoplasms; Chromatography, High Pr | 1985 |